"This concept could reshape how GLP-1RAs are prescribed across different disease states." The field is evolving in four directions at once: oral formulations, multi-agonist combinations, muscle preservation strategies, and expansion into disease areas beyond metabolic medicine
Most resolve within the first month as the body adapts to the medication
CC: Writing review and editing
"There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance." she said
Rinaman said that her laboratory discovered that the GLP-1 neurons in the rodent hindbrain are suppressedthat is, their ability to be activated is reducedduring states of negative energy balance, for example, after 18 hours of fasting in rats or mice (Maniscalco and Rinaman, 2018)